Loubet, Paul http://orcid.org/0000-0002-1218-9432
Wittkop, Linda http://orcid.org/0000-0003-2403-0960
Tartour, Eric http://orcid.org/0000-0002-7323-468X
Parfait, Beatrice
Barrou, Benoit
Blay, Jean-Yves http://orcid.org/0000-0001-7190-120X
Hourmant, Maryvonne
Lachâtre, Marie
Laplaud, David-Axel
Laville, Martine
Laviolle, Bruno
Lelievre, Jean-Daniel
Morel, Jacques
Nguyen, Stéphanie
Spano, Jean-Philippe
Terrier, Benjamin
Thiebaut, Anne
Viallard, Jean-Francois
Vrtovsnik, François
de Lamballerie, Xavier
Launay, Odile
Funding for this research was provided by:
Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S, ANRS00001S)
Article History
First Online: 12 July 2021
Competing interests
: P.L. has received personal fees as a speaker or consultant from Pfizer and Astrazeneca. J.M. has received honoraria as a speaker or consultant of less than €8,000 from Abbvie, Biogen, Bristol Myers Squibb, Boerhinger Ingelheim, Galapagos, GlaxoSmithKline, Fresenius Kabi, Lilly, Mylan, Novartis, Pfizer and Sanofi, and grants (outside the submitted work) from Lilly and Novartis. J.P.S. has received personal fees as a speaker or consultant from Pfizer and Astrazeneca. O.L. has received personal fees from Sanofi Pasteur; grants, personal fees and non-financial support from Pfizer, Janssen and Sanofi Pasteur–Merck Sharp & Dohme; and grants and non-financial support from GlaxoSmithKline.
Free to read: This content has been made available to all.